Key Takeaways: Hot flashes affect up to 80% of menopausal women and the average woman has them for 7-10 years. Systemic estradiol is the most effective treatment, cutting frequency by roughly 75%. Among non-hormonal options, fezolinetant reduces moderate-to-severe flashes by about 60%, low-dose paroxetine 7.5 mg is the only FDA-approved SSRI for vasomotor symptoms, and venlafaxine 75 mg and gabapentin 900 mg perform similarly at 45-50% reduction. Relief typically begins in 2-4 weeks with estrogen and by week 4 with fezolinetant.
Hot Flashes Are the Most Common Menopause Symptom — and the Most Treatable
Roughly 80% of women experience hot flashes or night sweats during the menopause transition. About a third describe them as severe. The average duration, per the SWAN cohort, is 7-10 years — not the "couple of years" most women are told to expect.
The good news is that vasomotor symptoms are also the single most treatable menopausal complaint. Almost every meaningful therapy — hormonal and non-hormonal — was built around them.
This article ranks the options by efficacy, explains how fast each one works, and walks through who should choose what.
What Causes a Hot Flash
Hot flashes are not caused by high body temperature. They are triggered by a narrowing of the thermoneutral zone in the hypothalamus, specifically in KNDy (kisspeptin/neurokinin B/dynorphin) neurons. When estrogen withdraws at menopause, these neurons become hyperactive, and tiny changes in core temperature trigger a full heat-dissipation response — flushing, sweating, peripheral vasodilation, and often a heart-rate spike.
Two therapeutic strategies drop out of this mechanism:
- Restore estrogen. Estradiol calms KNDy neurons and widens the thermoneutral zone.
- Block neurokinin-3 signaling directly. This is the mechanism of fezolinetant — it bypasses hormones entirely.
Every other treatment — SSRIs, SNRIs, gabapentin, clonidine — works upstream on the nervous system without directly fixing the hypothalamic signal.
Efficacy Ranking: What the Trials Actually Show
| Treatment |
Mean Reduction vs Baseline |
Time to Onset |
FDA Approved for VMS |
| Transdermal estradiol (0.05-0.1 mg) |
70-90% |
2-4 weeks |
Yes |
| Oral estradiol (0.5-1 mg) |
60-75% |
2-4 weeks |
Yes |
| Fezolinetant 45 mg |
~60% |
1-4 weeks |
Yes (2023) |
| Venlafaxine 75 mg |
45-50% |
2-4 weeks |
No (off-label) |
| Paroxetine 7.5 mg |
35-45% |
2-4 weeks |
Yes (Brisdelle) |
| Gabapentin 900 mg |
40-50% |
1-2 weeks |
No (off-label) |
| Clonidine 0.1 mg |
30-40% |
2-4 weeks |
No (off-label) |
| Placebo |
20-30% |
— |
— |
Placebo response for hot flashes is unusually high (often 25-30%). This is why any "menopause supplement" with a small open-label trial should be discounted heavily. If a product claims a 30% reduction, it is essentially matching placebo.
HRT: The Most Effective Option
Systemic estrogen is the gold standard. In the MsFLASH randomized trial, low-dose oral estradiol 0.5 mg/day reduced hot flash frequency by 53% at 8 weeks, versus 29% with placebo [1]. Larger doses and longer durations push the response toward 75-90%.
Transdermal vs Oral
Transdermal estradiol — patch, gel, or spray — is preferred over oral for most women because it:
- Produces steady serum estradiol levels (oral creates daily peaks)
- Avoids first-pass liver metabolism, which reduces the increase in clotting factors
- Carries lower stroke and VTE risk in observational data
- Is more convenient (twice-weekly patch or daily gel)
A typical starting regimen:
- Estradiol patch 0.05 mg/day, changed twice weekly, or
- Estradiol gel 0.5-1 mg/day applied to the forearm
Dose can be titrated up to 0.075-0.1 mg/day for women with severe symptoms.
Progestogen If You Have a Uterus
Unopposed estrogen raises endometrial cancer risk. Any woman with a uterus taking systemic estrogen needs a progestogen. The preferred agent is oral micronized progesterone 100-200 mg at bedtime — it is bioidentical, supports sleep, and does not appear to negatively affect breast or cardiovascular outcomes the way medroxyprogesterone did in the original WHI [2].
For a deeper comparison, see our bioidentical vs synthetic HRT guide.
Timeline
- Weeks 1-2: Intensity begins to drop; night sweats often respond first.
- Weeks 3-6: Frequency drops meaningfully. Sleep improves.
- Weeks 8-12: Peak response. If still symptomatic, dose is likely too low.
If you have not improved by 6 weeks on a 0.05 mg patch, the next steps are: verify absorption (serum estradiol of 50-80 pg/mL is a reasonable target), check adherence, and consider escalating to 0.075 or 0.1 mg.
Non-Hormonal Options: When HRT Is Off the Table
Not everyone can take estrogen. Absolute or relative contraindications include active estrogen-sensitive breast cancer, recent VTE or stroke, and active liver disease. Many women also simply prefer to avoid hormones.
The 2023 NAMS nonhormone therapy position statement gave Level I (highest) recommendations to cognitive behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin, and fezolinetant [3]. These are the evidence-backed choices.
Fezolinetant: The Newest and Most Targeted
Fezolinetant is a neurokinin-3 receptor antagonist — it blocks the KNDy neuron signal directly. FDA approved in May 2023, it is the first truly mechanism-targeted non-hormonal therapy.
In the SKYLIGHT 1 phase 3 trial of 527 women with at least 7 moderate-to-severe hot flashes per day, fezolinetant 45 mg reduced frequency by about 60% at week 12, versus 40% for placebo [4]. Onset is fast — many women see improvement within the first week.
- Dose: 45 mg once daily
- Monitoring: Liver enzymes at baseline, 3 months, 6 months, 9 months
- Cost: Expensive without insurance (often $500+/month); covered by many commercial plans
- Drawbacks: Headache, abdominal pain, mild transaminase elevation in a small minority
Fezolinetant is the best choice for a woman who wants near-HRT-level efficacy without hormones and is willing to accept the monitoring and cost.
Paroxetine 7.5 mg (Brisdelle)
The only SSRI with FDA approval for vasomotor symptoms. Low-dose paroxetine at 7.5 mg at bedtime is sub-therapeutic for depression but effective for hot flashes, reducing frequency by roughly 40% versus placebo in registration trials.
- Onset: 2-4 weeks
- Best for: Women with hot flashes plus mild mood symptoms who cannot take estrogen
- Avoid: Concurrent tamoxifen use — paroxetine inhibits CYP2D6 and reduces tamoxifen activation
Venlafaxine 75 mg
An SNRI. In the MsFLASH head-to-head trial against low-dose oral estradiol, venlafaxine reduced hot flashes by 48% versus 53% for estradiol, and 29% for placebo [1]. The gap between estradiol and venlafaxine was small and not clinically meaningful.
- Dose: 37.5 mg for 1 week, then 75 mg daily
- Best for: Women with mood, anxiety, or neuropathic pain components
- Drawbacks: Discontinuation syndrome if stopped abruptly; nausea early on
Gabapentin 900 mg
Originally developed as an anticonvulsant. Works well for women whose hot flashes cluster at night. In a 200-woman RCT, gabapentin 300 mg three times daily reduced hot flash scores by 51% versus 26% for placebo at 4 weeks [5].
- Dose: 300 mg at bedtime for 3 nights, then 300 mg morning and bedtime, then 300 mg three times daily
- Best for: Nocturnal hot flashes, women with insomnia or restless legs
- Drawbacks: Daytime drowsiness and mild unsteadiness in the first 2 weeks
Clonidine
An alpha-2 adrenergic agonist, primarily a blood pressure medication. Reduces hot flashes by 30-40%. Rarely first-line anymore given better alternatives, but useful if a woman also has hypertension.
What Does Not Work
The 2023 NAMS statement specifically did not recommend:
- Paced respiration (Level I negative)
- Soy extracts, black cohosh, wild yam cream (insufficient evidence)
- Cooling techniques, trigger avoidance, exercise alone (not effective for the symptom itself, though exercise has other benefits)
- Supplements and herbal products without rigorous trial data
This is worth internalizing. The menopause supplement aisle is essentially a placebo industry.
Choosing Between HRT and Non-Hormonal Therapy
The decision usually falls along these lines:
| Patient Profile |
First-Line Choice |
| No contraindications, symptoms moderate-to-severe |
Transdermal estradiol + micronized progesterone |
| Intact uterus, wants oral route |
Oral estradiol 0.5-1 mg + micronized progesterone |
| Breast cancer history, estrogen-sensitive |
Fezolinetant or venlafaxine |
| Mild symptoms plus significant anxiety/depression |
Venlafaxine 75 mg |
| Nocturnal-predominant symptoms, poor sleep |
Gabapentin 900 mg at bedtime |
| Wants non-hormonal, budget unlimited |
Fezolinetant 45 mg |
| Wants non-hormonal, insurance-constrained |
Venlafaxine or gabapentin generic |
For women with breast cancer history, also discuss vaginal estrogen separately — it is often safe even in this population. See our vaginal estrogen and GSM guide.
Dose Titration and Monitoring
HRT
- Baseline: estradiol, FSH, TSH, lipid panel, blood pressure
- Week 6-8 follow-up: symptom check, adjust dose if needed
- Annual: breast exam, mammogram per screening guidelines, endometrial assessment if persistent bleeding
- Serum estradiol target: 50-80 pg/mL is reasonable for symptom control
Fezolinetant
- Baseline: LFTs (ALT, AST)
- Month 3, 6, 9: repeat LFTs
- Discontinue if ALT >3x upper limit of normal
SSRIs/SNRIs
- Start at the lowest dose
- Reassess at 4 and 8 weeks
- Taper off gradually if discontinuing — do not stop abruptly
What to Do While You Wait for the Medication to Work
Lifestyle levers will not fix moderate-to-severe hot flashes, but they reduce frequency and trigger intensity in the transition period:
- Layered clothing, cool bedroom. Core temperature swings less in a 65-68°F room.
- Limit alcohol, especially red wine. Alcohol is one of the strongest triggers.
- Caffeine timing. Afternoon coffee prolongs wakefulness and amplifies overnight flashes.
- Weight loss if BMI >30. Adipose tissue generates heat and worsens vasomotor symptoms; modest weight loss improves them.
- Paced breathing for acute episodes. It does not reduce overall frequency, but slow diaphragmatic breathing during a flash shortens it.
For weight-related effects specifically, see our HRT and weight gain article.
A Typical Week 1 Plan
- Get baseline labs: estradiol, FSH, TSH, CBC, lipids, fasting glucose, A1C, ferritin.
- Start transdermal estradiol 0.05 mg/day patch, changed twice weekly.
- If you have a uterus, add oral micronized progesterone 100 mg at bedtime (200 mg if cyclic regimen).
- Keep a 2-week hot flash log: count per day, note triggers.
- Schedule 6-week follow-up to assess and titrate.
Women who need faster relief or cannot take estrogen should start fezolinetant or venlafaxine on day 1 with the same logging approach.
Special Populations
Women with Breast Cancer History
Systemic HRT is generally avoided. First-line options are fezolinetant, venlafaxine, or gabapentin. Paroxetine should be avoided in women on tamoxifen due to CYP2D6 interaction. Vaginal estrogen, which has minimal systemic absorption, is often considered safe per ACOG for severe genitourinary symptoms in this population.
Women Under 45 (Early Menopause or Premature Ovarian Insufficiency)
HRT is recommended until at least the average age of menopause (51-52) unless contraindicated. The risk-benefit calculus is very different — you are replacing hormones you should still have, not adding them.
Perimenopause with Variable Symptoms
Fluctuating ovarian function means symptoms come and go. Low-dose continuous transdermal estradiol can stabilize the swings. See our perimenopause timeline article for detailed staging.
Finding a Provider
A good provider for hot flash treatment:
- Will trial HRT first in eligible women rather than defaulting to SSRIs
- Prefers transdermal over oral estradiol
- Uses micronized progesterone, not medroxyprogesterone
- Is familiar with fezolinetant and the 2023 NAMS guidelines
- Reassesses at 6-8 weeks and adjusts dose based on response
Many general gynecologists still practice WHI-era prescribing and underdose or avoid HRT. Midlife-focused telehealth clinics are often more current. Compare vetted options at the best online HRT clinic for women review.
The Bottom Line
Hot flashes are overwhelmingly treatable. The efficacy hierarchy is consistent across every well-designed trial: systemic estradiol is most effective at about 75% reduction, fezolinetant is a strong non-hormonal second at 60%, and SSRIs/SNRIs/gabapentin cluster at 45-50%.
For most women without contraindications, transdermal estradiol plus oral micronized progesterone is the fastest path to relief. For women who cannot or will not take hormones, fezolinetant has changed the standard of care — it is nearly as effective and does not touch the hormonal system.
The wrong answer is "learn to live with it." Modern menopause medicine has five evidence-backed options that each cut symptoms by half or more. Pick one, follow it for 12 weeks, and adjust.
Related Reading
References:
- Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174(7):1058-66. PMID: 24861828
- Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. PMID: 12117397
- The 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-590. PMID: 37252752
- Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-1102. PMID: 36924778
- Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause. 2008;15(2):310-8. PMID: 17917611
- The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-992. PMID: 32852449